Skip to content
2000
Volume 14, Issue 8
  • ISSN: 1389-5575
  • E-ISSN: 1875-5607

Abstract

The emergence of drug resistant strains of important human pathogens has created an urgent necessity to find new targets and novel antitubercular agents. According to the literature survey, we noticed that enoyl ACP reductase is one of the most promising targets. This enzyme is the most important catalyst for the FAS II synthesis of mycolic acid, which is the most essential component of the mycobacterial cell wall. This review summarizes the progress made in the design of enoyl ACP reductase inhibitors and the role played by 3D-structure of the enzyme in drug design process.

Loading

Article metrics loading...

/content/journals/mrmc/10.2174/1389557514666140820112524
2014-06-01
2025-10-09
Loading full text...

Full text loading...

/content/journals/mrmc/10.2174/1389557514666140820112524
Loading

  • Article Type:
    Research Article
Keyword(s): Drug design; Enoyl ACP reductase; Enoyl ACP reductase inhibitors; FAS-II
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test